# Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

> **NCT03245905** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03245905
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-20
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245905, "Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03245905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*